Imipenem, Cilastatin and Relebactam is indicated for:
Population group: only adults (18 years old or older)
Imipenem/cilastatin/relebactam combination is indicated for treatment of hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP), in adults.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only adults (18 years old or older)
Imipenem/cilastatin/relebactam combination is indicated for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only adults (18 years old or older)
Imipenem/cilastatin/relebactam combination is indicated in patients 18 years of age and older who have limited or no alternative treatment options, for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by the following susceptible gram-negative microorganisms: Enterobacter cloacae, Escherichia coli, Klebsiella aerogenes, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
Approval of this indication is based on limited clinical safety and efficacy data for imipenem/cilastatin/relebactam.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only adults (18 years old or older)
Imipenem/cilastatin/relebactam combination is indicated in patients 18 years of age and older who have limited or no alternative treatment options for the treatment of complicated intra-abdominal infections (cIAI) caused by the following susceptible gram-negative microorganisms: Bacteroides caccae, Bacteroides fragilis, Bacteroides ovatus, Bacteroides stercoris, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Fusobacterium nucleatum, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Parabacteroides distasonis, and Pseudomonas aeruginosa.
Approval of this indication is based on limited clinical safety and efficacy data for imipenem/cilastatin/relebactam.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Imipenem, Cilastatin and Relebactam is contraindicated in the following cases:
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
